Cabozantinib
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Take orally 60 mg once daily on an EMPTY STOMACH: at least 1 hour before or 2 hours after food with a glass of water. Swallow whole.
⚠️ Side Effects
Common: Diarrhea, fatigue, hand-foot syndrome, hypertension, weight loss, nausea, dysgeusia, stomatitis. Rare/Severe: Gastrointestinal perforation and fistulas, severe hemorrhage, arterial thromboembolic events, and posterior reversible encephalopathy syndrome (PRES).
🛡️ Safety Warnings
Black Box Warning: Gastrointestinal perforations, fistulas, and severe hemorrhage. Discontinue permanently if perforation or severe fistula develops. Stop treatment at least 28 days prior to scheduled elective surgery. Monitor for severe hypertension.
Jan Aushadhi Products containing Cabozantinib
Found 3 generic formulation(s) containing this active ingredient.
Cabozantinib Tablets 20 mg
Cabozantinib Tablets (20mg, 40mg, 60mg) is an oral multi-tyrosine kinase inhibitor targeting MET, VEGFR-1/2/3, RET, AXL, KIT, and TIE-2 on the PMBI formulary. Simultaneous inhibition of MET and AXL overcomes resistance pathways commonly triggered by VEGF-only blockade. Indicated for advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy, hepatocellular carcinoma (HCC) previously treated with sorafenib, and progressive medullary thyroid cancer.
Cabozantinib Tablets 40 mg
Cabozantinib Tablets (20mg, 40mg, 60mg) is an oral multi-tyrosine kinase inhibitor targeting MET, VEGFR-1/2/3, RET, AXL, KIT, and TIE-2 on the PMBI formulary. Simultaneous inhibition of MET and AXL overcomes resistance pathways commonly triggered by VEGF-only blockade. Indicated for advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy, hepatocellular carcinoma (HCC) previously treated with sorafenib, and progressive medullary thyroid cancer.
Cabozantinib Tablets 60 mg
Cabozantinib Tablets (20mg, 40mg, 60mg) is an oral multi-tyrosine kinase inhibitor targeting MET, VEGFR-1/2/3, RET, AXL, KIT, and TIE-2 on the PMBI formulary. Simultaneous inhibition of MET and AXL overcomes resistance pathways commonly triggered by VEGF-only blockade. Indicated for advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy, hepatocellular carcinoma (HCC) previously treated with sorafenib, and progressive medullary thyroid cancer.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Cabozantinib.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Cabozantinib Tablets 20 mg | 30's bottle | ₹1453.13 | Cabdual, Cabolong, Caboneal | ₹5079.50 | 71% Save |
| Cabozantinib Tablets 40 mg | 30's bottle | ₹2296.88 | CABTIRO, KABONIB, CABOTRES | ₹8587.89 | 73% Save |
| Cabozantinib Tablets 60 mg | 30's bottle | ₹3562.50 | CABOZANIB, CABERZ, CABOTRES | ₹14301.87 | 75% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Cabozantinib generics.